More recently, the combination of anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) has been approved by the US FDA for use in unresectable HCC based on the results of HIMALAYA [105]. This evidence concerns the gene CD274 and hepatocellular carcinoma.